Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.54 |
| ▸ | NOS1 | P29475 | 6/20 | 0.54 |
| ▸ | NOS3 | P29474 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ARG2 | P78540 | 4/20 | 0.44 |
| ▸ | ARG1 | P05089 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059526 | 1.00 | NOS2 (0.54) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL5520220 | 1.00 | NOS2 (0.54) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL1331744 | 0.94 | GSR (0.52) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL1331746 | 0.94 | GSR (0.52) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL28469394 | 0.82 | NOS2 (0.56) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL10707233 | 0.82 | NOS2 (0.39) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL9713674 | 0.81 | NOS1 (0.51) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL9713664 | 0.81 | NOS1 (0.51) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL9713668 | 0.81 | NOS1 (0.51) | NOS2NOS1NOS3MEN1CYP2C19 | |
| SCHEMBL7220293 | 0.80 | NOS2 (0.54) | NOS2NOS1NOS3MEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114040986-A | Method of diagnosing disease | 4D制药科克有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-20250115963-A1 | Nucleic Acids, Methods and Kits for the Diagnosis of DYT6 Primary Torsion Dystonia | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-04-10 | — | — | US | disclosed |
| US-12188091-B2 | Nucleic acids, methods and kits for the diagnosis of DYT6 primary torsion dystonia | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-01-07 | — | — | US | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20230043763-A1 | Nucleic Acids, Methods and Kits for the Diagnosis of DYT6 Primary Torsion Dystonia | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-02-09 | — | — | US | disclosed |
| US-11421275-B2 | Nucleic acids, methods and kits for the diagnosis of DYT6 primary torsion dystonia | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220128556-A1 | METHODS OF DIAGNOSING DISEASE | 4D Pharma Cork Limited (IE) | 2022-04-28 | — | — | US | disclosed |
| CN-114040986-A | Method of diagnosing disease | 4D制药科克有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| US-20050049182-A1 | Therapeutic formulation comprising cationic peptide, viscosity-increasing agent, and solvent, wherein the cationic peptide contains up to 35 amino acids; use in treating or preventing infectious disease associated with foreign bodies, primary or seconary infection sites | MICROLOGIX BIOTECH INC. (CA) | 2005-03-03 | — | — | US | disclosed |
| US-6835536-B2 | Therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, in the treatment of microorganism-caused infections, which infections may be systemic, such as a | MICROLOGIX BIOTECH INC. (CA) | 2004-12-28 | — | — | US | disclosed |
| EP-1469876-A2 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF | Micrologix Biotech, Inc. (CA) | 2004-10-27 | — | — | EP | disclosed |
| US-20040106785-A1 | Inhibitors of RNA dependent RNA polymerase and uses thereof | MICROLOGIX BIOTECH INC. (CA) | 2004-06-03 | — | — | US | disclosed |
| WO-2003015809-A9 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF | MICROLOGIX BIOTECH INC (CA) | 2004-04-22 | — | — | WO | disclosed |
| US-20030219854-A1 | Methods for producing modified anti-infective peptides | MICROLOGIX BIOTECH INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| US-20030171281-A1 | Therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, in the treatment of microorganism-caused infections, which infections may be systemic, such as a | MICROLOGIX BIOTECH INC. (CA) | 2003-09-11 | — | — | US | disclosed |
| WO-2003015809-A2 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF | MICROLOGIX BIOTECH INC. (CA) | 2003-02-27 | — | — | WO | disclosed |
| EP-0638583-A1 | Aminosugar active substances, a process for their preparation and use as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-02-15 | — | — | EP | disclosed |
| EP-0253245-B1 | BIOLOGICALLY ACTIVE PEPTIDES TAN-866 | Takeda Chemical Industries, Ltd. (JP) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106785-A1 | Inhibitors of RNA dependent RNA polymerase and uses thereof | POLRMT, POLM, POLR2E | NOS2 4062/4885NOS1 3724/4885NOS3 3621/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | NOS2 641/4885NOS1 112/4885NOS3 1124/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | NOS2 641/4885NOS1 112/4885NOS3 1124/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | NOS2 641/4885NOS1 112/4885NOS3 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.